Trader Poll

Which M&A deal is best for shareholders?

2014 has been a blockbuster year for mergers and acquisitions so far. February alone saw global M&A deals worth $251 billion - the most since 2012, according to Standard Life Investment.

Among the biggest names in the news, Bayer said it will acquire the consumer care business of U.S.-based Merck for $14.2 billion in cash and General Electric offered $12.5 billion for the energy arm of French industrial engineering firm Alstom.

Read MoreM&A fever– the coming epidemic

Meanwhile, Pfizer remains in focus as it struggles to gain control of U.K. rival AstraZeneca with a $106 billion offer.

Out of these three deals, which represents the best value for shareholders?